In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer

D. Colcher, D. E. Milenic, P. Ferroni, J. A. Carrasquillo, J. C. Reynolds, M. Roselli, S. M. Larson, J. Schlom

Research output: Contribution to journalArticlepeer-review


Radiolabeled B72.3 (anti-TAG-72) has been shown to selectively localize metastatic lesions in 70%-80% of the cases. Serum samples from 27 colorectal carcinoma patients who received iodine-131- (131I) B72.3 by i.v. administration were analyzed. Circulating immunoreactive antibody followed a biphasic clearance pattern. High-performance liquid chromatography (HPLC) and SDS-polyacrylamide gel electrophoresis demonstrated that 131I-B72.3 retained its integrity in the patients' sera. HPLC analysis also demonstrated the presence of immune complexes in the sera of 12 patients; this correlated with elevated levels of circulating TAG-72. Several different HAMA response patterns were detected in the 25 patients' sera that were analyzed; some patients developed HAMA as early as 5-7 days post-MAb injection. Higher doses of administered MAb B72.3 correlated with the development of HAMA (p = 0.007). The presence of elevated levels of TAG-72 in the patients' pre-inoculum serum was shown to correlate with the detection of lesions by gamma scanning. Serum TAG-72 may serve as a criteria for patient selection for immunodiagnostic or immunotherapeutic procedures using MAb B72.3.

Original languageEnglish
Pages (from-to)1133-1142
Number of pages10
JournalJournal of Nuclear Medicine
Issue number7
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology


Dive into the research topics of 'In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer'. Together they form a unique fingerprint.

Cite this